Purity >95%. Renal glucose transport is mediated by sodium-glucose cotransporters (SGLT) 1 and 2. In humans, SGLT2 is responsible for the majority of glucose reabsorption in the kidney. galacto-Dapagliflozin is a potent inhibitor of human SGLT2 that is 1,000-fold less potent at human SGLT1 (Ki values are 2 and 25,000 nM, respectively). It also dissociates from hSGLT2 more slowly than from hSGLT1 (half-time off rates are 19 and 0.9 seconds, respectively).